Redhill Biopharma Ltd (RDHL NASDAQ) stock market data APIs
$0.9259
0.02(2.2%)
as of March 6, 2026
Try our APIs with
free plan!
Redhill Biopharma Ltd Financial Data Overview
Price chart is built with
Anychart
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Prev. Close
0.9259
Open
0.9435
High
0.9619
Low
0.9137
52 wk Range
0.8802-3.3099
Market Cap
4 704 K
P/E Ratio
0
Shares Outstanding
5 113 K
Revenue
9 550 K
EPS
0
Beta
4.988
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Redhill Biopharma Ltd data using free add-ons & libraries
Get Redhill Biopharma Ltd Fundamental Data
Redhill Biopharma Ltd Fundamental data includes:
- Net Revenue: 9 550 K
- EBITDA: -8 336 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-12
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Redhill Biopharma Ltd News
New
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of t...
RedHill Biopharma regains Nasdaq stockholders’ equity compliance
* RedHill Biopharma (RDHL [https://seekingalpha.com/symbol/RDHL]) has regained compliance [https://seekingalpha.com/pr/20323207-redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockhold...
RedHill received Talicia licensing payments totaling $1.1 million
* RedHill Biopharma (NASDAQ:RDHL [https://seekingalpha.com/symbol/RDHL]) on Monday announced that it has received its first Talicia ex-U.S. sales milestone, royalties and other payments totaling ...
Form 6K Redhill Biopharma Ltd For: 18 August
Get Redhill Biopharma Ltd fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
